UCB has launched Neupro for PD and restless legs; Relday moves into clinical trials;

> UCB has launched Neupro, its transdermal rotigotine delivery system, in the U.S. for the treatment of idiopathic Parkinson's disease and restless legs syndrome. Press release

> R-Tech Ueno and Tohoku University are developing an ocular drug delivery system for R-Tech Ueno's isopropyl unoprostone for the treatment of retinitis pigmentosa. Press release

> BioTime has signed an exclusive sublicense and supply agreement with Jade Therapeutics for an ophthalmological therapeutic sustained-release drug delivery platform, HyStem hydrogels. Press release

> Zogenix has started a clinical trial for Relday, which combines risperidone with its DosePro needle-free, subcutaneous drug delivery system. Press release

> Delivering dexamethasone via Mercator's micro-infusion catheter inhibits restenosis for at least 9 months in peripheral vascular disease (PAD). Press release

> MedPro Safety Products has signed a letter of intent with an undisclosed specialty pharmaceutical company to license its drug delivery platform, including an automated passive safety syringe. Press release

> Fucose-bound nanoparticles could target anticancer drug delivery to pancreatic cancer cells. Abstract

And Finally… Drugs could be delivered by remote control--an implantable drug delivery device has successfully delivered hormone treatment under wireless control. Article